A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies

Abstract Background Type 1 diabetes is characterised by the immune-mediated destruction of pancreatic beta cells. We aimed to determine the effectiveness of immunotherapies for preserving residual beta cell function in newly diagnosed (stage 3) type 1 diabetes. Methods Searches were carried out in M...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophie E. Beese, Malcolm J. Price, Claire Tomlinson, Pawana Sharma, Isobel M. Harris, Ada Adriano, Lauren M. Quinn, Ritu Gada, Thomas J. Horgan, Fiona Maggs, Martin Burrows, Krishnarajah Nirantharakumar, G. Neil Thomas, Robert C. Andrews, David J. Moore, Parth Narendran
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12916-025-04201-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238298972651520
author Sophie E. Beese
Malcolm J. Price
Claire Tomlinson
Pawana Sharma
Isobel M. Harris
Ada Adriano
Lauren M. Quinn
Ritu Gada
Thomas J. Horgan
Fiona Maggs
Martin Burrows
Krishnarajah Nirantharakumar
G. Neil Thomas
Robert C. Andrews
David J. Moore
Parth Narendran
author_facet Sophie E. Beese
Malcolm J. Price
Claire Tomlinson
Pawana Sharma
Isobel M. Harris
Ada Adriano
Lauren M. Quinn
Ritu Gada
Thomas J. Horgan
Fiona Maggs
Martin Burrows
Krishnarajah Nirantharakumar
G. Neil Thomas
Robert C. Andrews
David J. Moore
Parth Narendran
author_sort Sophie E. Beese
collection DOAJ
description Abstract Background Type 1 diabetes is characterised by the immune-mediated destruction of pancreatic beta cells. We aimed to determine the effectiveness of immunotherapies for preserving residual beta cell function in newly diagnosed (stage 3) type 1 diabetes. Methods Searches were carried out in MEDLINE, Embase, Cochrane CENTRAL and trial registries until 31st Jul 2024. RCTs of immunotherapies to preserve beta cells in newly diagnosed type 1 diabetes were included. Data were extracted using a bespoke, piloted extraction sheet. Risk of bias was assessed using Cochrane Risk of Bias Tool 1. A random effects network meta-analysis was undertaken in R. The primary outcome was C-peptide. Interventions were analysed by class. Results Sixty trials were included (4597 patients, 32 intervention classes). Forty-one trials of 42 interventions were eligible for network meta-analysis. Eleven interventions demonstrated statistically significantly higher levels of C-peptide than placebo at 12 months, mesenchymal stem cells (autologous and Wharton’s jelly-derived cells), azathioprine, interferon-alpha (5000 IU), autologous dendritic cells, anti-TNF golimumab, low-dose ATG, 3 mg 1-course anti-CD3 teplizumab, baricitinib, cyclosporin and 9/11 mg 2-course anti-CD3 teplizumab but with substantial heterogeneity present (I 2 = 66%). Azathioprine ranked highest (median ranking 3rd); however, rankings demonstrated relatively wide confidence intervals and thus uncertainty in exact rank order of near adjacent therapies. Risk of bias assessment identified poor reporting, particularly in older trials, but few studies demonstrated high risk overall. Conclusions Eleven of 42 interventions demonstrated statistically significantly higher C-peptide levels than placebo at 12 months in the network meta-analysis. These results have identified the 11 most promising therapies trialled and help to direct future head-to-head clinical trials to support approvals for interventions to treat those newly diagnosed with type 1 diabetes. However, data for some interventions originated from small studies (mesenchymal stem cell therapies, azathioprine, autologous dendritic cells) and findings should be considered as hypothesis generating and interpreted with caution due to evidence heterogeneity. Systematic review registration The protocol for the systematic review was registered on PROSPERO, the international database of prospectively registered systematic reviews (registration: CRD42018107904).
format Article
id doaj-art-5532d4dd5bd34a868a3556f047ab0db2
institution Kabale University
issn 1741-7015
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series BMC Medicine
spelling doaj-art-5532d4dd5bd34a868a3556f047ab0db22025-08-20T04:01:41ZengBMCBMC Medicine1741-70152025-07-0123112810.1186/s12916-025-04201-zA systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapiesSophie E. Beese0Malcolm J. Price1Claire Tomlinson2Pawana Sharma3Isobel M. Harris4Ada Adriano5Lauren M. Quinn6Ritu Gada7Thomas J. Horgan8Fiona Maggs9Martin Burrows10Krishnarajah Nirantharakumar11G. Neil Thomas12Robert C. Andrews13David J. Moore14Parth Narendran15Department of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Immunology and Immunotherapy, University of Birmingham, and University Hospitals Birmingham NHS Foundation TrustDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Oral and Maxillofacial Surgery, Shrewsbury and Telford Hospital NHS TrustDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamUniversity of Exeter Medical SchoolDepartment of Applied Health Sciences, School of Health Sciences, University of BirminghamDepartment of Immunology and Immunotherapy, University of Birmingham, and University Hospitals Birmingham NHS Foundation TrustAbstract Background Type 1 diabetes is characterised by the immune-mediated destruction of pancreatic beta cells. We aimed to determine the effectiveness of immunotherapies for preserving residual beta cell function in newly diagnosed (stage 3) type 1 diabetes. Methods Searches were carried out in MEDLINE, Embase, Cochrane CENTRAL and trial registries until 31st Jul 2024. RCTs of immunotherapies to preserve beta cells in newly diagnosed type 1 diabetes were included. Data were extracted using a bespoke, piloted extraction sheet. Risk of bias was assessed using Cochrane Risk of Bias Tool 1. A random effects network meta-analysis was undertaken in R. The primary outcome was C-peptide. Interventions were analysed by class. Results Sixty trials were included (4597 patients, 32 intervention classes). Forty-one trials of 42 interventions were eligible for network meta-analysis. Eleven interventions demonstrated statistically significantly higher levels of C-peptide than placebo at 12 months, mesenchymal stem cells (autologous and Wharton’s jelly-derived cells), azathioprine, interferon-alpha (5000 IU), autologous dendritic cells, anti-TNF golimumab, low-dose ATG, 3 mg 1-course anti-CD3 teplizumab, baricitinib, cyclosporin and 9/11 mg 2-course anti-CD3 teplizumab but with substantial heterogeneity present (I 2 = 66%). Azathioprine ranked highest (median ranking 3rd); however, rankings demonstrated relatively wide confidence intervals and thus uncertainty in exact rank order of near adjacent therapies. Risk of bias assessment identified poor reporting, particularly in older trials, but few studies demonstrated high risk overall. Conclusions Eleven of 42 interventions demonstrated statistically significantly higher C-peptide levels than placebo at 12 months in the network meta-analysis. These results have identified the 11 most promising therapies trialled and help to direct future head-to-head clinical trials to support approvals for interventions to treat those newly diagnosed with type 1 diabetes. However, data for some interventions originated from small studies (mesenchymal stem cell therapies, azathioprine, autologous dendritic cells) and findings should be considered as hypothesis generating and interpreted with caution due to evidence heterogeneity. Systematic review registration The protocol for the systematic review was registered on PROSPERO, the international database of prospectively registered systematic reviews (registration: CRD42018107904).https://doi.org/10.1186/s12916-025-04201-zSystematic reviewNetwork meta-analysisType 1 diabetesBeta cells
spellingShingle Sophie E. Beese
Malcolm J. Price
Claire Tomlinson
Pawana Sharma
Isobel M. Harris
Ada Adriano
Lauren M. Quinn
Ritu Gada
Thomas J. Horgan
Fiona Maggs
Martin Burrows
Krishnarajah Nirantharakumar
G. Neil Thomas
Robert C. Andrews
David J. Moore
Parth Narendran
A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
BMC Medicine
Systematic review
Network meta-analysis
Type 1 diabetes
Beta cells
title A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
title_full A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
title_fullStr A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
title_full_unstemmed A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
title_short A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies
title_sort systematic review and network meta analysis of interventions to preserve insulin secreting beta cell function in people newly diagnosed with type 1 diabetes results from randomised controlled trials of immunomodulatory therapies
topic Systematic review
Network meta-analysis
Type 1 diabetes
Beta cells
url https://doi.org/10.1186/s12916-025-04201-z
work_keys_str_mv AT sophieebeese asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT malcolmjprice asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT clairetomlinson asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT pawanasharma asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT isobelmharris asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT adaadriano asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT laurenmquinn asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT ritugada asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT thomasjhorgan asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT fionamaggs asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT martinburrows asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT krishnarajahnirantharakumar asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT gneilthomas asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT robertcandrews asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT davidjmoore asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT parthnarendran asystematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT sophieebeese systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT malcolmjprice systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT clairetomlinson systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT pawanasharma systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT isobelmharris systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT adaadriano systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT laurenmquinn systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT ritugada systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT thomasjhorgan systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT fionamaggs systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT martinburrows systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT krishnarajahnirantharakumar systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT gneilthomas systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT robertcandrews systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT davidjmoore systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies
AT parthnarendran systematicreviewandnetworkmetaanalysisofinterventionstopreserveinsulinsecretingbetacellfunctioninpeoplenewlydiagnosedwithtype1diabetesresultsfromrandomisedcontrolledtrialsofimmunomodulatorytherapies